Vmbook Online ordering

Immunoclin Corporation

ImmunoClin Therapeutics, Inc. (IMCL) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel therapies for the treatment of cancer and inflammatory diseases. The company's lead product candidate is ICT01, a monoclonal antibody targeting the CD25 protein, which is overexpressed in certain types of cancer and in autoimmune diseases.

In terms of financials, ImmunoClin reported a net loss of $5.6 million for the third quarter of 2021, compared to a net loss of $4.1 million for the same period in 2020. As of September 30, 2021, the company had cash and cash equivalents of $22.3 million.

The company is still in preclinical and early-stage clinical development and has not yet generated any revenue from product sales. The company's main focus is to advance the development of its lead product candidate and to explore opportunities for partnerships and collaborations.

It is important to note that investing in the stock market, especially in biotech and pharmaceutical companies, can be risky and it's recommended to conduct your own research or consult a financial advisor before making any investment decisions.

Also, the information provided here is based on public data as of specific date and may change over time, so it is recommended to check the latest financial statements and regulatory filings on the SEC's EDGAR database or the company's website for more up-to-date information.